SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue guidance, attributed to sustained demand for Amtagvi and Proleukin, is driving attention as traders view it as evidence of commercial growth and improving execution. The reaction is broadly bullish, though some question whether the update is already priced in and look to upcoming lung-cancer data as another catalyst.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQures additional 48-month AMT-130 data for Huntingtons disease is driving attention: cUHDRS slowing weakened versus the 36-month results and did not reach statistical significance, prompting a sharp selloff. Traders debate whether the longer-term results reflect patient dropouts and changes in the external comparator, while bulls argue the FDA-aligned 36-month data remains the basis for the accelerated-approval filing.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing are fueling concern that competition could weaken FICOs longstanding mortgage-scoring advantage and revenue. Traders are split between viewing the selloff as a lasting threat to the moat and calling it an overreaction, citing FICOs broader software business and continued growth.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and clinical collaboration to test ivonescimab in gastrointestinal cancers are driving attention, with traders viewing the deal as financing relief and a strong vote of confidence. Some caution that it is not an acquisition and that the separate FDA decision remains uncertain, while others warn of a possible sell-the-news reaction.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop ultra-high-voltage silicon carbide devices and validate domestic manufacturing is driving attention. Bulls see the award as meaningful technology and government validation, while skeptics note it is a prototype program with no disclosed financial terms or clear near-term revenue; short-squeeze hopes and sell-the-news concerns add to the debate.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp rebound has fueled breakout chatter, with bullish traders pointing to Zebecs payroll and payments partnershipsincluding MoneyGramas support for its adoption story. Others remain skeptical about weak price follow-through and real-world usage, while speculation about a Robinhood tie-up is unconfirmed.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rally and rising volume have revived breakout talk, with traders pointing to broader altcoin momentum and the tokenization/institutional-adoption narrative, including reported NYSE testing of Avalanche technology. Others doubt the move is supported by lasting demand and warn it could fade as a speculative pump.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix reported an 89% complete-response rate in the 45-patient NEXICART-2 update, with all 25 newer patients in complete response or MRD-negative and no relapses or neurotoxicity reported to date. Traders welcomed the clinical results but debated the concurrent registered offering and its potential dilution.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has sparked buyout speculation, though traders disagree on whether it signals anything beyond routine executive protections and there is no confirmed deal. The discussion also reflects concern about the lack of a shipment or launch date for BlueBirds 1416 and uncertainty around BlueBird 11s deployment.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CROs sharp rebound toward the seven-cent resistance level has fueled breakout talk, with traders pointing to Crypto.coms reported Citadel Securities investment and Cronos app plans as possible tailwinds. Others question whether the move can hold, citing concerns about token supply expansion and Crypto.com leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Gets China Approval For Etripamil Nasal Spray

(RTTNews) - Milestone Pharmaceuticals (MIST) on Thursday announced that China's National Medical Products Administration has approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. Etripamil is marketed in the U.S. as CARDAMYST...

Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that China's National Medical Products
Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults. The NMPA decision marks the first regulatory approval of e...

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -16.67% and -30.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding...

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -433.33% and -99.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-milestone-pharmaceuticals-inc-stock...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 10,325,577 shares, an...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has...

Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was sold at an average...

This account has been verified as an official MIST representative.

Verified Account

Milestone Pharma ($MIST)

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/

Milestone Pharmaceuticals Inc

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Equity

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.22	--	--	N/A
Q2 '26	-$0.19	-$0.21	-7.69%	MISSED
Q1 '26	$0.19	-$0.20	-205.26%	MISSED
Q4 '25	-$0.16	-$0.16	0.12%	BEAT
Q3 '25	-$0.16	-$0.12	26.83%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MIST Earnings

Upcoming Earnings: Q3 '26

Historical Earnings